Citigroup Inc Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$233.81 - $287.01 $4.51 Million - $5.54 Million	19,300 Added 170.8%	30,600 $8.42 Million
Q2 2024 Aug 12, 2024	SELL	$143.31 - $247.0 $6.41 Million - $11 Million	-44,700 Reduced 79.82%	11,300 $2.75 Million
Q1 2024 May 10, 2024	BUY	$146.51 - $198.2 $4.54 Million - $6.14 Million	31,000 Added 124.0%	56,000 $8.37 Million
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $772,191 - $1 Million	5,100 Added 25.63%	25,000 $4.79 Million
Q3 2023 Nov 09, 2023	BUY	$170.77 - $211.65 $3.4 Million - $4.21 Million	19,900 New	19,900 $3.52 Million
Q4 2022 Feb 09, 2023	BUY	$185.53 - $241.31 $3.19 Million - $4.15 Million	17,200 Added 49.43%	52,000 $12.4 Million
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $4.82 Million - $8.07 Million	34,800 New	34,800 $6.97 Million
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $2.34 Million - $3.2 Million	18,400 New	18,400 $3.01 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.